SIHUAN PHARM (00460) has announced that five additional specifications of its self-developed sodium hyaluronate composite solution for injection (skin booster, trade name: Dongyan), developed by its subsidiary Meiyan Space Biotechnology (Jilin) Co., Ltd. (Meiyan Space), have officially received approval for market launch from China's National Medical Products Administration.
The approval of these new specifications represents a significant milestone following the product's market launch and further strengthens the group's product portfolio and competitiveness in the lightweight medical aesthetics skin booster segment.
As China's first facial composite solution skin booster containing L-carnosine, Dongyan features core ingredients including hyaluronic acid, L-carnosine, multiple amino acids, and vitamin B2. It offers multiple benefits such as hydration and moisture retention, antioxidant effects, anti-glycation, anti-inflammation, and promotion of collagen regeneration. Administered through intradermal facial injection, it effectively improves skin dryness and dullness, catering to the general public's lightweight medical aesthetics skincare needs and covering a broad consumer base.
Prior to this specification expansion, the product's approved specifications included 0.5mL per vial, 1.0mL per vial, 1.5mL per vial, 2.0mL per vial, 2.5mL per vial, 3.0mL per vial, and 5mL per box (containing two 2.5mL per vial products), totaling seven specifications. The newly approved specifications of 0.75mL per vial, 1.25mL per vial, 1.75mL per vial, 2.25mL per vial, and 2.75mL per vial effectively fill the gaps in the original dosage range, forming a complete gradient and comprehensively covering product dosage spectrum.
Key value and significance of this specification expansion
1. Meeting diversified skin needs and enriching clinical application scenarios: The new specifications fill the dosage gaps of the original product, accommodating various clinical scenarios such as localized fine-area superficial care, full-face basic maintenance, and combined regenerative filling treatments. For different facial care areas, skin dullness conditions, and individual tolerance differences among consumers, it provides clinicians with more precise dosage options, better matching the personalized skin improvement needs of consumers across different age groups and skin conditions.
2. Improving product matrix and strengthening segment synergy advantages: As a core essential category in lightweight medical aesthetics, skin booster products feature broad market potential and prominent user repurchase characteristics. China's lightweight medical aesthetics skin booster sub-market continues to develop steadily, with industry consumption and clinical demand gradually upgrading toward standardization and personalization. With the full implementation of Dongyan's complete gradient dosage product matrix, it can strengthen business synergy with the group's other product categories including botulinum toxin, collagen stimulator,少女针 (girl needle), and gold microneedle, flexibly combining to form "filling regeneration + skin quality repair" integrated anti-aging solutions. Leveraging its mature marketing channel network covering over 370 cities nationwide and cooperating with over 9,000 medical institutions, it will further solidify Meiyan Space's full-category operational advantages and market competitiveness in the lightweight medical aesthetics sector.
3. Facilitating standardized and refined industry development: As domestic medical aesthetics consumption concepts continue to upgrade, industry services have gradually shifted from traditional models toward customized and differentiated personalized treatment plans. The approval and market launch of these gradient dosage specifications can provide effective reference for the specification research and development and product iteration of similar Class III medical device skin booster products in China, helping promote high-quality and refined industry development.
Meiyan Space is a "one-stop" innovative medical aesthetics platform carefully incubated by SIHUAN PHARM. Through a global layout, comprehensive and professional medical aesthetics product matrix, and an integrated architecture covering product research and development, registration, production, and sales, it is committed to building a leading enterprise in China's medical aesthetics full-product matrix with the rigorous innovation of a pharmaceutical company. Meiyan Space continues to build a complete product matrix covering the full lifecycle needs of beauty enthusiasts through a dual-engine drive of "self-research + BD," with over 60 products in its pipeline covering basic categories of lightweight medical aesthetics including filling, shaping, support, photoelectric devices, and skin management. Meanwhile, Meiyan Space possesses strong independent research and development and technology transfer capabilities, with its domestic and international professional BD teams and research and development teams able to rapidly advance the development and implementation of medical aesthetics products. Currently, Meiyan Space has established three production bases globally, with a comprehensive quality management system and effective risk management throughout the product lifecycle. Its experienced medical aesthetics sales team, nationwide broad-coverage sales network, and deep development system can rapidly advance product sales. Most members of Meiyan Space's sales team come from multinational medical aesthetics and pharmaceutical companies, possessing rich experience in medical aesthetics product sales, and closely cooperating with dozens of distributors, with a sales network covering over 370 cities and over 9,000 medical aesthetics institutions nationwide.